Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and holds organs as well as joints together. It is characterised by thickened and harder skin due to an overabundance of collagen leading to scars. Scar tissue builds up in organs including the heart and blood vessels, as well as the lungs, stomach, and kidneys, causing damage.Females are four times more likely than males to experience Scleroderma leading to an increased market share of drugs. Know more about the disease, its symptoms, epidemiological insights, marketed therapies and treatment modalities through the newsletter. DelveInsight brings to focus a rare skin disorder, ongoing R&amp;D related activities like pipeline product assessment and upcoming novel therapies to treat this condition.The newsletter outlines a complete picture of the Scleroderma market landscape, major pharma players involved, pipeline therapies, unmet needs and clinical trials in process. Our newsletter also compiles the recent happenings, news coverage in the market domain along with top notch conferences expected in the near future.Download our newsletter by filling up the form towards the right and stay informed regarding the Scleroderma market.Get the newsletter directly mailed to your email box by filling up a simple form towards your right. Join our Newsletter series and get rich insights delivered every week to you.Stay tuned for more.

Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and holds organs as well as joints together. It is characterised by thickened and harder skin due to an overabundance of collagen leading to scars. Scar tissue builds up in organs including the heart and blood vessels, as well as the lungs, stomach, and kidneys, causing damage.

Scleroderma

The Scleroderma newsletter outlines a complete picture of the Scleroderma market landscape, major pharma players involved, pipeline therapies, unmet needs and clinical trials in process. 